Brian Haddigan: Beyond Stent Design – The Importance of Blood Compatibility
Brian Haddigan, Chief Executive Officer and Co Founder at Smart Reactors, shared a post on LinkedIn:
“What if the next breakthrough in venous stents isn’t the design, but the surface?
FDA post-market surveillance continues to receive reports of thrombosis, occlusion and restenosis associated with venous stents.
While these reports don’t measure complication rates, they reinforce that blood compatibility remains an important challenge.
Smart Reactors we’ve developed Camouflage, an ultra-thin, non-pharmacological hemocompatible coating designed to create a more blood-friendly surface, reducing platelet and fibrin adhesion while supporting natural healing.
The future of vascular implants includes solid engineering and smarter surfaces.
Could your next-generation device benefit from Camouflage?
Lets connect and find out..”

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines